Skip to content

Author

M. Snuderl

We have 4 of 515 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Identification and characterization of a novel distinct Pineal Neoplasm with Neuroendocrine and Epithelial Differentiation (PINNED)

Pineal region tumors are rare neoplasms that occur in all ages and account for less than 1% of all central nervous system (CNS) tumors in adults but are more frequent in children. Here, we describe a previously unrecognized tumor type of pineal origin characterized by a unique and consistent DNA methylation profile tha...

Helena Bode, A. Suwala, B. Gudenas et al. · 0 citations
Open access Jun 2024

Medulloblastoma Spatial Transcriptomics Reveals Tumor Microenvironment Heterogeneity with High-Density Progenitor Cell Regions Correlating with High-Risk Disease

The tumor microenvironment (TME) of medulloblastoma (MB) influences progression and therapy response, presenting a promising target for therapeutic advances. Prior single-cell analyses have characterized the cellular components of the TME but lack spatial context. To address this, we performed spatial transcriptomic se...

F. Chien, Marina E. Michaud, Mojtaba Bakhtiari et al. · 5 citations
Open access Oct 2026

Medulloblastoma Spatial Transcriptomics Reveals Tumor Microenvironment Heterogeneity With High-Density Progenitor Cell Regions Correlating With High-Risk Disease.

PURPOSE No curative options are available for medulloblastoma (MB) in the relapse setting. The tumor microenvironment (TME) influences progression and therapy response, presenting a promising target for therapeutic advances. Prior single-cell analyses have characterized the cellular components of the TME but lack spati...

F. Chien, Marina E. Michaud, Mojtaba Bakhtiari et al. · 0 citations
Review Sep 2026

Genome Profiling of Actionable Cancer Targets (NYU LG-PACT) for Clinical Patient Molecular Diagnostics and Treatment

The technical challenges of validating an NGS oncological diagnostic targeted assay for clinical grade accuracy and sensitivity for patient care are presented and how copy number alterations provide a more comprehensive description of the tumors genomic profile are shown.

Y. Yang, V. Vasudevaraja, J. Serrano et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.